Cargando…

Inhibition of Phosphoglycerate Dehydrogenase Radiosensitizes Human Colorectal Cancer Cells under Hypoxic Conditions

SIMPLE SUMMARY: Colorectal cancer is the third most prevalent cancer worldwide. Treatment options for these patients consist of surgery combined with chemotherapy and/or radiotherapy. However, a subset of tumors will not respond to therapy or acquire resistance during the course of the treatment, le...

Descripción completa

Detalles Bibliográficos
Autores principales: Van de Gucht, Melissa, Dufait, Inès, Kerkhove, Lisa, Corbet, Cyril, de Mey, Sven, Jiang, Heng, Law, Ka Lun, Gevaert, Thierry, Feron, Olivier, De Ridder, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599856/
https://www.ncbi.nlm.nih.gov/pubmed/36291844
http://dx.doi.org/10.3390/cancers14205060
_version_ 1784816696454807552
author Van de Gucht, Melissa
Dufait, Inès
Kerkhove, Lisa
Corbet, Cyril
de Mey, Sven
Jiang, Heng
Law, Ka Lun
Gevaert, Thierry
Feron, Olivier
De Ridder, Mark
author_facet Van de Gucht, Melissa
Dufait, Inès
Kerkhove, Lisa
Corbet, Cyril
de Mey, Sven
Jiang, Heng
Law, Ka Lun
Gevaert, Thierry
Feron, Olivier
De Ridder, Mark
author_sort Van de Gucht, Melissa
collection PubMed
description SIMPLE SUMMARY: Colorectal cancer is the third most prevalent cancer worldwide. Treatment options for these patients consist of surgery combined with chemotherapy and/or radiotherapy. However, a subset of tumors will not respond to therapy or acquire resistance during the course of the treatment, leading to patient relapse. The interplay between reprogramming cancer metabolism and radiotherapy has become an appealing strategy to improve a patient’s outcome. Due to the overexpression of certain enzymes in a variety of cancer types, including colorectal cancer, the serine synthesis pathway has recently become an attractive metabolic target. We demonstrated that by inhibiting the first enzyme of this pathway, namely phosphoglycerate dehydrogenase (PHGDH), tumor cells that are deprived of oxygen (as is generally the case in solid tumors) respond better to radiation, leading to increased tumor cell killing in an experimental model of human colorectal cancer. ABSTRACT: Augmented de novo serine synthesis activity is increasingly apparent in distinct types of cancers and has mainly sparked interest by investigation of phosphoglycerate dehydrogenase (PHGDH). Overexpression of PHGDH has been associated with higher tumor grade, shorter relapse time and decreased overall survival. It is well known that therapeutic outcomes in cancer patients can be improved by reprogramming metabolic pathways in combination with standard treatment options, for example, radiotherapy. In this study, possible metabolic changes related to radioresponse were explored upon PHGDH inhibition. Additionally, we evaluated whether PHGDH inhibition could improve radioresponse in human colorectal cancer cell lines in both aerobic and radiobiological relevant hypoxic conditions. Dysregulation of reactive oxygen species (ROS) homeostasis and dysfunction in mitochondrial energy metabolism and oxygen consumption rate were indicative of potential radiomodulatory effects. We demonstrated that PHGDH inhibition radiosensitized hypoxic human colorectal cancer cells while leaving intrinsic radiosensitivity unaffected. In a xenograft model, the first hints of additive effects between PHGDH inhibition and radiotherapy were demonstrated. In conclusion, this study is the first to show that modulation of de novo serine biosynthesis enhances radioresponse in hypoxic colorectal cancer cells, mainly mediated by increased levels of intracellular ROS.
format Online
Article
Text
id pubmed-9599856
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95998562022-10-27 Inhibition of Phosphoglycerate Dehydrogenase Radiosensitizes Human Colorectal Cancer Cells under Hypoxic Conditions Van de Gucht, Melissa Dufait, Inès Kerkhove, Lisa Corbet, Cyril de Mey, Sven Jiang, Heng Law, Ka Lun Gevaert, Thierry Feron, Olivier De Ridder, Mark Cancers (Basel) Article SIMPLE SUMMARY: Colorectal cancer is the third most prevalent cancer worldwide. Treatment options for these patients consist of surgery combined with chemotherapy and/or radiotherapy. However, a subset of tumors will not respond to therapy or acquire resistance during the course of the treatment, leading to patient relapse. The interplay between reprogramming cancer metabolism and radiotherapy has become an appealing strategy to improve a patient’s outcome. Due to the overexpression of certain enzymes in a variety of cancer types, including colorectal cancer, the serine synthesis pathway has recently become an attractive metabolic target. We demonstrated that by inhibiting the first enzyme of this pathway, namely phosphoglycerate dehydrogenase (PHGDH), tumor cells that are deprived of oxygen (as is generally the case in solid tumors) respond better to radiation, leading to increased tumor cell killing in an experimental model of human colorectal cancer. ABSTRACT: Augmented de novo serine synthesis activity is increasingly apparent in distinct types of cancers and has mainly sparked interest by investigation of phosphoglycerate dehydrogenase (PHGDH). Overexpression of PHGDH has been associated with higher tumor grade, shorter relapse time and decreased overall survival. It is well known that therapeutic outcomes in cancer patients can be improved by reprogramming metabolic pathways in combination with standard treatment options, for example, radiotherapy. In this study, possible metabolic changes related to radioresponse were explored upon PHGDH inhibition. Additionally, we evaluated whether PHGDH inhibition could improve radioresponse in human colorectal cancer cell lines in both aerobic and radiobiological relevant hypoxic conditions. Dysregulation of reactive oxygen species (ROS) homeostasis and dysfunction in mitochondrial energy metabolism and oxygen consumption rate were indicative of potential radiomodulatory effects. We demonstrated that PHGDH inhibition radiosensitized hypoxic human colorectal cancer cells while leaving intrinsic radiosensitivity unaffected. In a xenograft model, the first hints of additive effects between PHGDH inhibition and radiotherapy were demonstrated. In conclusion, this study is the first to show that modulation of de novo serine biosynthesis enhances radioresponse in hypoxic colorectal cancer cells, mainly mediated by increased levels of intracellular ROS. MDPI 2022-10-15 /pmc/articles/PMC9599856/ /pubmed/36291844 http://dx.doi.org/10.3390/cancers14205060 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Van de Gucht, Melissa
Dufait, Inès
Kerkhove, Lisa
Corbet, Cyril
de Mey, Sven
Jiang, Heng
Law, Ka Lun
Gevaert, Thierry
Feron, Olivier
De Ridder, Mark
Inhibition of Phosphoglycerate Dehydrogenase Radiosensitizes Human Colorectal Cancer Cells under Hypoxic Conditions
title Inhibition of Phosphoglycerate Dehydrogenase Radiosensitizes Human Colorectal Cancer Cells under Hypoxic Conditions
title_full Inhibition of Phosphoglycerate Dehydrogenase Radiosensitizes Human Colorectal Cancer Cells under Hypoxic Conditions
title_fullStr Inhibition of Phosphoglycerate Dehydrogenase Radiosensitizes Human Colorectal Cancer Cells under Hypoxic Conditions
title_full_unstemmed Inhibition of Phosphoglycerate Dehydrogenase Radiosensitizes Human Colorectal Cancer Cells under Hypoxic Conditions
title_short Inhibition of Phosphoglycerate Dehydrogenase Radiosensitizes Human Colorectal Cancer Cells under Hypoxic Conditions
title_sort inhibition of phosphoglycerate dehydrogenase radiosensitizes human colorectal cancer cells under hypoxic conditions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599856/
https://www.ncbi.nlm.nih.gov/pubmed/36291844
http://dx.doi.org/10.3390/cancers14205060
work_keys_str_mv AT vandeguchtmelissa inhibitionofphosphoglyceratedehydrogenaseradiosensitizeshumancolorectalcancercellsunderhypoxicconditions
AT dufaitines inhibitionofphosphoglyceratedehydrogenaseradiosensitizeshumancolorectalcancercellsunderhypoxicconditions
AT kerkhovelisa inhibitionofphosphoglyceratedehydrogenaseradiosensitizeshumancolorectalcancercellsunderhypoxicconditions
AT corbetcyril inhibitionofphosphoglyceratedehydrogenaseradiosensitizeshumancolorectalcancercellsunderhypoxicconditions
AT demeysven inhibitionofphosphoglyceratedehydrogenaseradiosensitizeshumancolorectalcancercellsunderhypoxicconditions
AT jiangheng inhibitionofphosphoglyceratedehydrogenaseradiosensitizeshumancolorectalcancercellsunderhypoxicconditions
AT lawkalun inhibitionofphosphoglyceratedehydrogenaseradiosensitizeshumancolorectalcancercellsunderhypoxicconditions
AT gevaertthierry inhibitionofphosphoglyceratedehydrogenaseradiosensitizeshumancolorectalcancercellsunderhypoxicconditions
AT feronolivier inhibitionofphosphoglyceratedehydrogenaseradiosensitizeshumancolorectalcancercellsunderhypoxicconditions
AT deriddermark inhibitionofphosphoglyceratedehydrogenaseradiosensitizeshumancolorectalcancercellsunderhypoxicconditions